Domov › Burkitov lymfóm › Illinois
Klinické štúdie Burkitov lymfóm v štáte Illinois
14 štúdií pre Burkitov lymfóm hľadá účastníkov v zariadeniach v štáte Illinois.
Mestá v štáte Illinois
Oficiálny text štúdie (anglicky)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- a 4 ďalších
Prebieha náborFáza 2
366 Days – 46 Years · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- a 7 ďalších
Prebieha náborFáza 3
Vek 18 až 39 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT03150693Blinatumomab Consolidation in Real World
- Northwestern University, Chicago
- The University of Chicago, Chicago
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07117136Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- a 9 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- a 3 ďalších
Prebieha náborFáza 2
365 Days · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- a 2 ďalších
Prebieha náborFáza 2
Vek 1 až 30 · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- a 5 ďalších
Prebieha náborFáza 3
365 Days – 25 Years · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Prebieha náborFáza 2
Vek 7 až 25 · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Chicago
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT06137118Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 13. 7. 2026 · NCT07109219Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
Prebieha náborFáza 2
Vek 18 až 54 · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06918431ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- University of Chicago Comprehensive Cancer Center, Chicago
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 11. 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Chicago, Chicago
Prebieha náborFáza 1/2
Vek 15 až 50 · Všetky pohlavia · Aktualizované 9. 9. 2025 · NCT04150497Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Prebieha nábor
Vek 18 až 50 · Všetky pohlavia · Aktualizované 19. 6. 2025 · NCT06785324Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.